Author: MyHairline Editorial Team Editorial review: MyHairline medical content review. Named clinician reviewer pending verified reviewer relationship and crawlable bio. Last updated: May 2026
Educational use only. This article is not medical advice. The Myhairline.ai analyzer is an educational classification tool and does not diagnose, treat, or prescribe. Treatment decisions belong with a board-certified dermatologist or qualified clinician.
Last March, a guy named Derek in Phoenix emailed us a photo of his bathroom counter: an iRestore helmet on one side, a Capillus cap still in its box on the other. "I bought both during a 2 a.m. panic scroll," he wrote. "My wife thinks I've lost it. Just tell me which one to keep and which one to return." Derek is 34, Norwood 3, and had been quoted $8,200 for a transplant he couldn't afford. His question, some version of "irestore vs capillus," shows up in our inbox almost daily.
Here's the thing: the answer is less exciting than either company's marketing suggests, and more useful because of it.
The Real Question Behind the Question
When someone Googles "irestore vs capillus," they usually want a clean winner. Product A beats Product B. Buy this one. But the comparison that matters isn't really iRestore versus Capillus. It's low-level laser therapy (LLLT) versus other treatments for hair loss, and whether either device delivers enough benefit to justify the price tag.
Both the iRestore and Capillus are consumer LLLT devices. Both use red-spectrum light (typically 650 to 680 nanometers). Both are cleared by the FDA via the 510(k) pathway. And that 510(k) distinction matters, because it means the FDA reviewed them for "substantial equivalence" to a predicate device, not through the more rigorous PMA approval process used for drugs like finasteride. The clearance tells you the device is probably safe. It doesn't tell you it works well.
So before we get into diode counts and session times, let's put the whole category in context.
Where Laser Caps Sit in the Evidence Hierarchy
The strongest non-surgical evidence for androgenetic alopecia belongs to two medications: finasteride and minoxidil. The 1998 finasteride trials published in the Journal of the American Academy of Dermatology (Kaufman et al.) and the 2002 minoxidil trials in the same journal (Olsen et al.) both demonstrated statistically significant improvements in hair counts versus placebo. These are the reference-standard studies. Decades of replication followed.
LLLT sits a tier below. Jimenez et al. published a randomized controlled trial in the American Journal of Clinical Dermatology in 2014 showing modest hair count improvements versus a sham device. The word "modest" is doing real work in that sentence. The effect sizes were smaller than those seen with finasteride or minoxidil, and the body of trial evidence is thinner. That doesn't mean laser caps are useless. It means they're a supporting actor, not the lead.
For PRP (platelet-rich plasma), a 2019 meta-analysis in the Journal of Dermatological Treatment pooled mixed-quality studies and found a small but statistically significant aggregate effect, with substantial heterogeneity across studies. Translation: some patients seem to respond, but the data is messy enough that no responsible clinician would call it a first-line therapy.
My genuinely held opinion: if you have early androgenetic alopecia and you're choosing between a $700 laser cap and a $15/month generic finasteride prescription, the finasteride is the smarter first move by a wide margin. The laser cap might be a reasonable add-on later. It is not a reasonable substitute.
The Actual Hardware Differences
That said, if you've already decided on a laser cap (or want one as an adjunct), the iRestore and Capillus do differ in ways worth knowing.
Diode count and energy output. The Capillus line ranges from around 202 diodes in the base model to over 300 in the premium CapillusPro. iRestore's Professional model advertises 282 laser and LED diodes combined. More diodes theoretically means more even scalp coverage and more total energy per session, but "theoretically" is the operative word. No head-to-head clinical trial has compared these two brands directly. We're extrapolating from general LLLT principles.
Wavelength. Both brands cluster around 650 to 680 nm, which is the range studied in published LLLT trials. Neither brand deviates dramatically from the studied protocol here.
Treatment time. Capillus sessions run about 6 minutes. iRestore sessions typically run 25 minutes. That's a significant daily-life difference, especially for compliance over months. Hair loss treatment only works if you actually do it, and a 6-minute protocol has a compliance advantage over a 25-minute one. Think of it like flossing: the best version is the one you'll actually use.
Form factor. The Capillus is a flexible cap that fits under a regular baseball hat. The iRestore is a rigid helmet. The Capillus is more discreet, more portable. The iRestore looks like something from a low-budget sci-fi film. This matters if you plan to use it while doing other things around the house or if you travel frequently.
Price. Both brands have tiered pricing. Entry models start around $600 to $700; premium models push past $1,000 to $3,000. At the high end, you're spending transplant-deposit money on a device whose best clinical evidence shows modest improvements.
Warranty and return policy. Both companies have offered money-back guarantees of varying lengths. Check the current terms before purchasing, because these change frequently and the fine print (photo documentation requirements, timeline restrictions) can be more demanding than the marketing suggests.
What 510(k) Clearance Really Means
Both iRestore and Capillus display "FDA cleared" prominently. It is worth understanding what that means and, more importantly, what it doesn't.
The 510(k) pathway requires a manufacturer to demonstrate that a new device is substantially equivalent to a legally marketed predicate device. It does not require clinical trials proving efficacy for that specific product. Some LLLT manufacturers have conducted their own clinical studies, and those studies vary considerably in size, design, and independence. But the 510(k) clearance itself is not a stamp of clinical effectiveness. It's a regulatory safety gateway.
This is fundamentally different from how finasteride or minoxidil got to market. Those drugs went through Phase III clinical trials with hundreds of participants, placebo controls, and defined primary endpoints. The evidence bar is simply higher.
Compliance Is the Variable Nobody Wants to Talk About
Most comparison articles focus on specs. The boring truth is that the biggest predictor of outcome with any hair loss treatment is whether the patient keeps using it. Finasteride works if you take it daily. Minoxidil works if you apply it consistently. Laser caps work (to the extent they work) if you actually put them on your head several times a week for months.
The Capillus's shorter session time and more wearable design may translate into better real-world compliance for some users. That's not a spec-sheet advantage. It's a behavioral one, and behavioral advantages compound over time.
Who These Devices Actually Make Sense For
Based on the evidence, a laser cap (either brand) makes the most sense for:
- Someone already on finasteride and/or minoxidil who wants a low-risk adjunct therapy
- Someone who cannot tolerate or refuses medication and accepts that the evidence for device-only treatment is weaker
- Someone in early stages of loss (Norwood 2 to 3, roughly) where follicles are miniaturizing but not fully dormant
Where these devices fall apart as a strategy: advanced loss (Norwood 5+), where the follicles are largely gone and no amount of red light is going to resurrect them. At that point, the conversation shifts to transplant surgery or cosmetic options.
Comparing Apples to Apples (and Why Most Reviews Don't)
A meaningful product comparison holds several variables constant: the patient profile (pattern, stage, sex, age), the use case (sole therapy vs. adjunct), the duration of use, and the outcome measure (hair count, density, patient satisfaction). Most online reviews vary all of these simultaneously, which makes their conclusions essentially meaningless.
Before-and-after photos without standardized lighting, angle, and timing are marketing materials, not evidence. Single-patient testimonials are anecdotes, not data. And "top 10" lists are typically structured around affiliate commissions rather than clinical merit.
The dermatology literature remains a more reliable source than product review sites. That's not a controversial opinion. It's just how evidence works.
Common Questions
Does iRestore or Capillus work better than minoxidil or finasteride? No. Both minoxidil and finasteride have substantially more replicated clinical trial evidence and larger demonstrated effect sizes than any consumer LLLT device. The medications are first-line; devices are adjunctive.
Is there a head-to-head study comparing iRestore and Capillus? Not that we've found in the peer-reviewed literature as of this update. Comparisons between the two brands are based on device specifications, general LLLT evidence, and user-reported experience rather than direct clinical trials.
Can a laser cap regrow hair on a bald scalp? Unlikely. LLLT appears to work primarily on miniaturizing follicles, not on follicles that have fully ceased producing hair. Advanced hair loss (Norwood 5+) is generally beyond what any laser device can address.
Does the Myhairline.ai analyzer diagnose hair loss? No. The analyzer is an educational classification tool. It does not diagnose, treat, or prescribe. A clinical diagnosis of any hair loss condition requires examination by a board-certified dermatologist.
Are the treatment claims in this article guarantees? No. Every treatment discussed has documented variability in outcome across patients. No medication, procedure, or device guarantees regrowth, and no responsible clinician or article should claim otherwise.
Is 510(k) clearance the same as FDA approval? No. The 510(k) pathway demonstrates substantial equivalence to a predicate device. It is a lower evidence bar than the PMA (Premarket Approval) process used for new drugs. Clearance indicates safety and substantial equivalence, not proven clinical efficacy for that specific product.
Should I talk to a dermatologist before buying a laser cap? Yes. A board-certified dermatologist can evaluate your pattern, stage, and contributing factors, then help you decide whether a device, medication, or combination approach makes the most sense for your specific situation.
Continue Reading
This article is part of the Comparisons & Decision-Making cluster on Myhairline.ai. The pillar overview is The Norwood Scale: Complete Guide to Male Pattern Hair Loss Stages, and the cluster hub is Comparisons & Decision-Making Cluster Hub.
Within this cluster:
- Tell Me About Hair Transplant Companies And Which Is Best: Complete Guide: a focused reference on tell me about hair transplant companies and which is best.
- Theradome Vs Capillus: a focused reference on theradome vs capillus.
- Hair Transplant Vs Medication Vs Lifestyle: a focused reference on hair transplant vs medication vs lifestyle.
Related from other clusters:
- Prp Hair Restoration Woodland Hills: Complete Guide: a focused reference on prp hair restoration woodland hills. (from the Non-Surgical Treatments cluster).
- Hair Transplant Cost In Turkey - Real Numbers: a focused reference on hair transplant cost in turkey. (from the Hair Transplant Cost & Process cluster).
Key References
Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology. 1998;39(4):578-589.
Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology. 2002;47(3):377-385.
Jimenez JJ, Wikramanayake TC, Bergfeld W, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss. American Journal of Clinical Dermatology. 2014;15(2):115-127.
Hamilton JB. Patterned loss of hair in man: types and incidence. Annals of the New York Academy of Sciences. 1951;53(3):708-728.
Norwood OT. Male pattern baldness: classification and incidence. Southern Medical Journal. 1975;68(11):1359-1365.